Eventide Asset Management, LLC Pharvaris N.V. Transaction History

Eventide Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$16.35 - $27.5 $2.41 Million - $4.06 Million	147,632 Added 48.78%	450,251 $9.95 Million
Q1 2022 May 16, 2022	BUY	$15.98 - $19.65 $921,950 - $1.13 Million	57,694 Added 23.56%	302,619 $5.66 Million
Q3 2021 Nov 15, 2021	SELL	$13.14 - $20.97 $3.9 Million - $6.22 Million	-296,638 Reduced 54.77%	244,925 $4.23 Million
Q2 2021 Aug 16, 2021	BUY	$18.05 - $29.59 $750,212 - $1.23 Million	41,563 Added 8.31%	541,563 $9.84 Million
Q1 2021 May 14, 2021	BUY	$25.25 - $40.11 $12.6 Million - $20.1 Million	500,000 New	500,000 $14 Million

39.6M

Ticker PHVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,766,000
Market Cap $636M
Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.